Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A straightforward rationale for incorporating Equal Weighted Indices into a portfolio, emphasizing diversification and simplicity.
22,501 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A targeted international dividend fund surged 26% over the past year and yields around 3.1%, while broad overseas exp...
XLY relies heavily on two megacaps, exposing the fund to outsized moves from Amazon and Tesla and prompting renewed q...
Nvidia could be headed toward a $300 stock price as AI demand, margins, and strategic bets align. This article breaks...
MONECO Advisors recently boosted its stake in a defined-maturity bond ETF, signaling a deliberate ladder strategy. Le...
When Broadcom's guidance disappointed, a sudden market pullback opened a legitimate AI buying opportunity. This artic...
When a large manager trims a position, questions follow. This article breaks down Hilton Capital’s $25 million GPIX s...
The trucking sector moves in tight cycles, and this week Knight-Swift Transportation faced a sharp price swing. Learn...
A blockbuster IPO can set the stage for more funding moves. This article explains why spacex raising more cash throug...
Insider moves can mislead, but context matters. This article explains why Nick Khan’s 9,589 share sale isn’t a warnin...
Looking to add serious income on the side? This guide covers 15 legitimate side hustles that can realistically pay $1...
Retirement planning isn’t only for retirees. The best practices for retirement planning at any age build a flexible, ...